» Articles » PMID: 35377003

Human Challenge Studies for Cholera

Overview
Date 2022 Apr 4
PMID 35377003
Authors
Affiliations
Soon will be listed here.
Abstract

The human challenge model permits an estimate of the vaccine protection against moderate and severe cholera. It eliminates the difficulty in setting up a vaccine study in endemic area including uncertainties about the incidence of cholera and the logistic arrangements for capturing those who do/do not become ill. Valuable information from small groups of subjects can be obtained in a short period. Under proper precautions and study design, the challenge model is safe and efficient. Although the model has evolved since it was introduced over 50 years ago, it has been used extensively to test vaccine efficacy. Vaccine licensure has resulted from data obtained using the human challenge model. In addition, the model has been used to: (1) Establish and validate a standardized inoculum, (2) Identify immune markers and immune responses, (3) Determine natural immunity (in re-challenge studies), (4) Identify the role of the gastric acid barrier in preventing cholera infection, (5) Show homologous and heterologous infection-derived immunity, and (6) Test the efficacy of anti-diarrheal/anti-secretory small molecules. The aim of this chapter is to present an overview on the state of the art for human challenge models used to study cholera and new medical interventions against it.

Citing Articles

Controlled human malaria infection: overview and potential application in the evaluation of transmission-blocking interventions in malaria-endemic areas.

Kessy E, Olotu A Malar J. 2025; 24(1):33.

PMID: 39893367 PMC: 11786456. DOI: 10.1186/s12936-025-05277-x.


Phase 1 Open-Label Dose Escalation Trial for the Development of a Human Bacillus Calmette-Guérin Challenge Model for Assessment of Tuberculosis Immunity In Vivo.

Blazevic A, Edwards R, Xia M, Eickhoff C, Hamzabegovic F, Meza K J Infect Dis. 2023; 229(5):1498-1508.

PMID: 38019956 PMC: 11095547. DOI: 10.1093/infdis/jiad441.


The Challenge Non-Typhoidal (CHANTS) Consortium: Development of a non-typhoidal controlled human infection model: Report from a consultation group workshop, 05 July 2022, London, UK.

Smith C, Smith E, Chiu C, Hinton J, Perez Sepulveda B, Gordon M Wellcome Open Res. 2023; 8:111.

PMID: 37808389 PMC: 10558987. DOI: 10.12688/wellcomeopenres.19012.2.

References
1.
Black R, Levine M, Clements M, Young C, Svennerholm A, Holmgren J . Protective efficacy in humans of killed whole-vibrio oral cholera vaccine with and without the B subunit of cholera toxin. Infect Immun. 1987; 55(5):1116-20. PMC: 260477. DOI: 10.1128/iai.55.5.1116-1120.1987. View

2.
Cash R, Music S, Libonati J, Craig J, Pierce N, Hornick R . Response of man to infection with Vibrio cholerae. II. Protection from illness afforded by previous disease and vaccine. J Infect Dis. 1974; 130(4):325-33. DOI: 10.1093/infdis/130.4.325. View

3.
Cash R, Music S, Libonati J, Snyder M, Wenzel R, Hornick R . Response of man to infection with Vibrio cholerae. I. Clinical, serologic, and bacteriologic responses to a known inoculum. J Infect Dis. 1974; 129(1):45-52. DOI: 10.1093/infdis/129.1.45. View

4.
Chen W, Garza J, Choquette M, Hawkins J, Hoeper A, Bernstein D . Safety and immunogenicity of escalating dosages of a single oral administration of peru-15 pCTB, a candidate live, attenuated vaccine against enterotoxigenic Escherichia coli and Vibrio cholerae. Clin Vaccine Immunol. 2014; 22(1):129-35. PMC: 4278929. DOI: 10.1128/CVI.00560-14. View

5.
Chen W, Cohen M, Kirkpatrick B, Brady R, Galloway D, Gurwith M . Single-dose Live Oral Cholera Vaccine CVD 103-HgR Protects Against Human Experimental Infection With Vibrio cholerae O1 El Tor. Clin Infect Dis. 2016; 62(11):1329-1335. PMC: 4872293. DOI: 10.1093/cid/ciw145. View